| Lipids Management |
1 |
1 |
| PCSK9 |
0 |
0.99 |
| Biologic Therapy |
0 |
0.43 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.38 |
| Cardiovascular Risk Management |
0 |
0.22 |
| Statins |
0 |
0.21 |
| Child |
0 |
0.16 |
| Monoclonal Antibody |
0 |
0.16 |
| Familial Hypercholesterolemia |
0 |
0.15 |
| Hypercholesterolemia |
0 |
0.11 |
| LDL Cholesterol |
0 |
0.98 |
| Clinical Research |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Face |
0 |
0.05 |
| Food and Drug Administration (FDA) |
0 |
0.05 |
| Hand |
0 |
0.05 |
| Heart |
0 |
0.05 |
| Insurance |
0 |
0.05 |
| Jobs |
0 |
0.05 |
| Lipoproteins |
0 |
0.05 |
| Medical Life |
0 |
0.05 |
| Pharmacokinetics |
0 |
0.05 |
| Plasma |
0 |
0.05 |
| Revenue and Practice Management |
0 |
0.05 |
| Washington |
0 |
0.05 |